ResMed Inc has declared an ordinary quarterly dividend of USD 0.06 per Chess Depositary Instrument, which equates to USD 0.60 per underlying NYSE share given the 10:1 CDI structure. The dividend relates to the company’s first quarter of 2026, ending 31 March, and will be payable on 18 June 2026 to shareholders on the record date of 14 May 2026, with an ex-date of 13 May 2026. The announcement carries price sensitivity flags from the ASX, indicating the market considers this material information for investment decisions.
For Australian CDI holders, several important considerations emerge from this distribution. The dividend is denominated in US dollars and carries a 30 percent withholding tax rate applicable to non-residents. Notably, the distribution is completely unfranked, with zero franking credits available to Australian investors. The Australian dollar equivalent value has not yet been determined, with ResMed indicating this information will be released by 15 May 2026 based on the exchange rate prevailing on the record date. This unfranked, foreign-sourced income structure means Australian taxpayers will need to include the full USD 0.06 per CDI value in their assessable income at the AUD conversion rate applicable on the payment date.
The quarterly frequency of this dividend demonstrates ResMed’s commitment to returning capital to shareholders on a regular basis. The timing of the announcement, made on 1 May 2026 for distributions relating to Q1 performance, reflects the company’s disciplined approach to dividend policy and its confidence in cash generation during the period. For income-focused investors holding ResMed through the ASX, this represents a meaningful yield component, though the unfranked nature means the effective after-tax yield will be lower than a franked Australian dividend of equivalent size. The withholding tax position means investors should factor in the 30 percent leakage when calculating expected income from the investment.
The ex-date of 13 May 2026 is the critical cutoff point for investors seeking to capture this dividend, falling approximately two weeks after this announcement. Any investor purchasing ResMed CDIs on or after this date will not be entitled to this distribution. The extended settlement period to 18 June provides the company with time to process dividend payments across its shareholder registry, though investors should expect the funds to arrive during mid-June depending on their broker’s processing procedures.
Investors tracking ResMed’s dividend policy should watch for the company’s earnings guidance in coming weeks, which will provide context for whether this quarterly distribution rate is sustainable or likely to change. The AUD equivalent figure released by 15 May will also allow local investors to quantify precisely what income the dividend represents in Australian dollar terms. This announcement is designated price sensitive and flagged as material by the ASX.
View the full ASX announcement (PDF)
About ResMed Inc (ASX: RMD)
ResMed Inc develops and manufactures medical devices and cloud-based software for diagnosing, treating, and managing respiratory disorders including sleep apnea, chronic obstructive pulmonary disease, and neuromuscular disease. The company supplies flow generators, masks, and accessories globally, with the majority of revenue derived from operations in the Americas. ResMed also pursues digital health initiatives and acquisitions to enhance clinical data offerings for patients, healthcare providers, and payers in out-of-hospital settings.
If you would like to discuss this announcement or how it might affect your portfolio, request a callback or call us on 1300 889 603.
